Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.
By K. Kelly, J. Crowley, P. Bunn, C. Presant, Patra K. Grevstad, C. Moinpour, Scott D. Ramsey, A. Wozniak, G. Weiss, D. Moore and 3 more. Journal of Clinical Oncology, 2001
1,141 citations recorded by the source corpus.
Subfields: Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/3d942839eb871bd9b06599d43cc00f59b0de94ef
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. (2012, background): “In general, survival in this study was comparable with historic results from trials in patients with advanced NSCLC.(4,5,9-11) In the ITT population, nab-PC was noninferior to sb-PC, with an approximately 10% improvement for PFS and OS favoring the nabPC arm.”
- Non-small cell lung cancer: current treatment and future advances. (2016, background): “Median overall survival for patients in these studies was approximately 8–10 months (35-38).”
- Immune Checkpoint Blockade in Cancer Therapy. (2015, background): “Although irAEs are different in character from adverse events caused by traditional chemotherapy or targeted therapy, the rate of grade 3 or 4 toxicity with immune checkpoint blockade (approximately 10% to 20%) is no greater than that seen with many standard chemotherapy or targeted therapy regimens”